EUVIMEDEUVIMED entdecken
Crossref

The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders

Meng Hsuan Kuo iD, Chih-Wei Tseng iD, Kuo-Chih Tseng iD, Ming-Chi Lu, Chien-Hsueh Tung, Nai-Tzu Chen, Kuang-Yung Huang, Ning-Sheng Lai

Liver International · 2025

DOI: 10.1111/liv.70152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Meng Hsuan Kuo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan. Hauptthemen laut MEDLINE: Virus Activation, Rheumatic Diseases, Tumor Necrosis Factor-alpha, Hepatitis B virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rheumatologic patients who test positive for hepatitis B surface antigen (HBsAg) or core antibody (HBcAb) are at risk of HBV reactivation when treated with TNF‐α inhibitors. The effect of TNF‐α inhibitor potency on this risk remains unclear, despite guidelines advising potency‐based risk stratification. This study examines how TNF‐α inhibitor potency influences the risk of HBV reactivation.

Methods

From January 2008 to June 2023, 711 new TNF‐α inhibitor users with rheumatic diseases were identified, including 39 HBsAg+ patients with antiviral prophylaxis, 72 HBsAg+ patients without antiviral prophylaxis, and 600 HBsAg−/HBcAb+ patients without prophylaxis. A Cox proportional hazards model assessed factors associated with HBV reactivation.

Results

Over 2526 person‐years of follow‐up, HBsAg+ patients without antiviral prophylaxis had the highest HBV reactivation rate at 104.1 per 1000 person‐years, followed by HBsAg−/HBcAb+ patients at 12.9, and HBsAg+ patients with antiviral prophylaxis at 12.6 per 1000 person‐years. Multivariate Cox regression revealed that high‐potency TNF‐α inhibitors significantly increased HBV reactivation risk in HBsAg+ patients without antiviral prophylaxis (aHR 3.24, 95% CI: 1.09–9.67, p = 0.04). Adalimumab had a higher reactivation risk compared to etanercept (aHR 3.23, 95% CI: 1.02–10.17, p = 0.04), followed by golimumab (aHR 3.27, 95% CI: 0.91–11.64, p = 0.07). For HBsAg−/HBcAb+ patients, TNF‐α inhibitor potency did not significantly impact HBV reactivation risk; instead, age over 65 was the only significant risk factor (aHR 3.37, 95% CI: 1.30–8.70, p = 0.01).

Conclusion

High‐potency TNF‐α inhibitors significantly increase HBV reactivation risk in HBsAg+ patients, while HBsAg−/HBcAb+ patients have a uniformly low risk across all inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus ActivationRheumatic DiseasesTumor Necrosis Factor-alphaHepatitis B virusAntirheumatic AgentsHepatitis BHumansFemaleMaleMiddle AgedHepatitis B Surface AntigensAgedAntiviral AgentsAdultProportional Hazards ModelsRetrospective StudiesHepatitis B AntibodiesTumor Necrosis Factor InhibitorsRisk Factors

Stichwörter der Autor:innen

HBV reactivationTNF‐α inhibitor potencyrheumatologic patients

Substanzen

Hepatitis B Surface AntigensTumor Necrosis Factor-alphaAntiviral AgentsAntirheumatic AgentsHepatitis B AntibodiesTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan.
  • School of Medicine, Tzuchi University, Hualien, Taiwan.
  • Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan.
  • Division of Rheumatology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan.

ORCID-Profile: Meng Hsuan Kuo, Chih-Wei Tseng, Kuo-Chih Tseng

Zitieren

APA

Kuo, M. H., Tseng, C. W., Tseng, K. C., Lu, M. C., Tung, C. H., Chen, N. T., Huang, K. Y., & Lai, N. S. (2025). The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders. Liver International. https://doi.org/10.1111/liv.70152

Vancouver

Kuo MH, Tseng CW, Tseng KC, Lu MC, Tung CH, Chen NT, et al. The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders. Liver International. 2025. doi:10.1111/liv.70152

BibTeX
@article{Kuo2025,
  author = {Kuo, Meng Hsuan and Tseng, Chih-Wei and Tseng, Kuo-Chih and Lu, Ming-Chi and Tung, Chien-Hsueh and Chen, Nai-Tzu and Huang, Kuang-Yung and Lai, Ning-Sheng},
  title = {The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70152}
}
Kostenlos starten →